Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02013687 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
A Phase 1 study, sponsored by Fraunhofer, Center for Molecular Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02013687 is a Phase 1 study that has completed, run by Fraunhofer, Center for Molecular Biotechnology. The registered enrollment target is 44 participants.
The verdict
NCT02013687, a Phase 1 study, has completed, sponsored by Fraunhofer, Center for Molecular Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
Interventions
- BIOLOGICAL Pfs25 VLP- FhCMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02013687
The ClinicalTrials.gov registry entry for NCT02013687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fraunhofer, Center for Molecular Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pfs25 VLP- FhCMB is the first listed.
NCT02013687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02013687 about?
NCT02013687 is a clinical study titled "Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults". This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
What is the current status of trial NCT02013687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2013-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02013687?
The interventions under investigation include: Pfs25 VLP- FhCMB (BIOLOGICAL).
Who is sponsoring clinical trial NCT02013687?
This trial is sponsored by Fraunhofer, Center for Molecular Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.